مباشر
FierceBiotechSummit's PD-1xVEGF interim trial miss surprises analysts, shares tumbleEndpoints NewsAcelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from ChinaEndpoints NewsSave the date: Premium subscriber-exclusive Post-Hoc LiveEndpoints NewsFDA approval for Alzheimer's agitation drug; Esperion goes private in $1.1B dealBioPharma DiveBristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookFierceBiotechCBER chief Prasad steps aside, deputy takes the reins as search for successor continuesFierceBiotechJ&J axes $5B CAR-T dream months after touting best-in-disease efficacyEndpoints NewsSummit slips on ivonescimab's apparent interim miss in sign of investor frustrationEndpoints NewsAmgen files update to Tavneos label as FDA escalates push to withdrawFierceBiotechChutes & Ladders—Astellas appoints new top strategist from Sanofi JapanFierceBiotechLigand tries to disembark from part of Viking pact, alleging contract breachCellBringing the genetically minimal cell to life on a computer in 4D
Endpoints News ١ مايو ٢٠٢٦

Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut

Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.